# Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome

> **NCT00452192** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 30 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT00452192
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452192, "Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00452192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*